{"id":"paclitaxel-micelles-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel is a taxane that binds to β-tubulin dimers within microtubules, promoting their assembly and preventing disassembly. This disrupts the dynamic instability of microtubules required for mitotic spindle formation and cell cycle progression, leading to G2/M phase arrest and apoptosis in cancer cells. The micellar formulation improves solubility and reduces hypersensitivity reactions compared to conventional paclitaxel.","oneSentence":"Paclitaxel micelles stabilize microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:21.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT06752811","phase":"PHASE3","title":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2025-02-05","conditions":"Pancreatic Cancer Metastatic","enrollment":416},{"nctId":"NCT06356688","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Jing","startDate":"2025-04-20","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT04778839","phase":"PHASE1","title":"Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-03-04","conditions":"Advanced Solid Tumors","enrollment":98},{"nctId":"NCT06199895","phase":"PHASE2","title":"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer","status":"RECRUITING","sponsor":"Liu Huang","startDate":"2023-11-28","conditions":"Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer","enrollment":25},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":"Metastatic Breast Cancer (MBC)","enrollment":168},{"nctId":"NCT06706895","phase":"PHASE2","title":"A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-12-01","conditions":"Advanced Gastric Cancer, Paclitaxel Polymeric Micelles for Injection, Fruquintinib Capsules","enrollment":21},{"nctId":"NCT05782426","phase":"PHASE2","title":"Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2023-03-15","conditions":"Non-squamous NSCLC","enrollment":28},{"nctId":"NCT02667743","phase":"PHASE3","title":"Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC","status":"UNKNOWN","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2015-05","conditions":"Non-Small Cell Lung Cancer(NSCLC)","enrollment":454},{"nctId":"NCT02064829","phase":"NA","title":"Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer","status":"COMPLETED","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2014-03","conditions":"Metastatic Breast Cancer, Locally Recurrent Breast Cancer","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Paclitaxel Micelles for Injection","genericName":"Paclitaxel Micelles for Injection","companyName":"Shanghai Yizhong Pharmaceutical Co., Ltd.","companyId":"shanghai-yizhong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel micelles stabilize microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}